Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Browse trials for

• Urinary Incontinence 1,363
• Urinary Bladder, Overactive 855

Keywords

• OAB
• Overactive Bladder
• Bladder hyperactivity
• Urge Incontinence
• Incontinence
• Bladder

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's enrollment of 395 is above the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.

Lead sponsor

Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.

Study arms

• Experimental
  1

  Darifenacin

  Drug: Darifenacin

• Other
  2

  Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder

  Drug: Darifenacin · Behavioral: Behavioral therapy

Interventions

• DrugDarifenacin

  Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily

  Also known as: Enablex

• DrugDarifenacin

  Darifenacin tablets 7,5 mg or 15 mg once daily

• BehavioralBehavioral therapy

  Behavioral Modification Programme for symptoms of overactive bladder

Primary outcomes

1. Change from baseline in average number of urinations per patient per day at Week 12

Secondary outcomes

1. Change from baseline in average number of urination episodes per patient per day at Week 2, Week 6

2. Change from baseline in average number of urge urinary incontinence episodes, urgency episodes, incontinence pads, and nocturnal urinations per day measured at Weeks 2, 6, 12

3. Quality of Life (baseline, Week 6, Week 12)